NBRV News and Press, Nabriva Therapeutics plc From 08/11/22

DUBLIN, Ireland and FORT WASHINGTON, Pa., Aug. 11, 2022 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, announced the completion of pati...

Nabriva Therapeutics plc (NBRV) Q2 2022 Results Conference Call August 03, 2022 04:30 PM ET Company Participants Dan Dolan - CFO Ted Schroeder - CEO Conference Call Participants Carl Byrnes - Northland Capital Markets Thomas Yip - HCW Presentati...

Nabriva Therapeutics press release ( NASDAQ: NBRV ): Q2 GAAP EPS of -$0.18 beats by $0.02 . Revenue of $9.19M (+11.5% Y/Y) beats by $0.66M . As of June 30, 2022, Nabriva had $20.2 million in cash, cash equivalents and restricted cash. Based on its current o...

-Net Product Sales of $8.7M Grew 25% versus Q2 2021- -SIVEXTRO Prescription Demand Grew 28% versus Q2 2021- -Conference Call Today at 4:30 p.m. Eastern Time- DUBLIN, Ireland, Aug. 03, 2022 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceut...

DUBLIN, Ireland and FORT WASHINGTON, Pa., July 20, 2022 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced that it will rep...

Nabriva Therapeutics ( NASDAQ: NBRV ) signed a distribution agreement with Er-Kim for the oral and intravenous formulations of its medicine Xenleta (lefamulin). Xenleta is used to treat adults with community-acquired bacterial pneumonia. Under the ag...

DUBLIN, Ireland and FORT WASHINGTON, Pa., July 18, 2022 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced that it has ente...

DUBLIN, Ireland, May 13, 2022 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced that Ted Schroeder, Chief Executive Office...

Nabriva Therapeutics plc (NBRV) Q1 2022 Earnings Conference Call May 05, 2022 04:30 PM ET Company Participants Dan Dolan - Chief Financial Officer Ted Schroeder - Chief Executive Officer Christine Guico-Pabia - Chief Medical Officer Conference Call Participants Carl Byrnes - Northland Capital...

Nabriva Therapeutics press release (NASDAQ:NBRV): Q1 GAAP EPS of -$0.20 misses by $0.01. Revenue of $8.02M (+218.3% Y/Y) misses by $1.55M. For further details see: Nabriva Therapeutics GAAP EPS of -$0.20 misses by $0.01, revenue of $8.02M misses by $1.55M